137 related articles for article (PubMed ID: 36366811)
1. Incidence and survival rates of primary uterine carcinosarcoma in Korea: a National Cancer Registry study.
Kim SI; Kim JH; Lee C; Ha J; Jung KW; Lim MC
J Gynecol Oncol; 2023 Jan; 34(1):e9. PubMed ID: 36366811
[TBL] [Abstract][Full Text] [Related]
2. Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea.
Ha HI; Kim JH; Lim J; Song YJ; Won YJ; Lim MC
J Gynecol Oncol; 2024 Jan; 35(1):e31. PubMed ID: 38072401
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
4. Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database.
Hosh M; Antar S; Nazzal A; Warda M; Gibreel A; Refky B
Int J Gynecol Cancer; 2016 Jul; 26(6):1098-104. PubMed ID: 27177280
[TBL] [Abstract][Full Text] [Related]
5. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
6. Incidence and treatment outcomes of uterine cervical cancer in Korea 1999-2018 from the national cancer registry.
Suh DH; Ha HI; Lee YJ; Lim J; Won YJ; Lim MC
J Gynecol Oncol; 2023 Mar; 34(2):e39. PubMed ID: 36731896
[TBL] [Abstract][Full Text] [Related]
7. Trends of uterine carcinosarcoma in the United States.
Matsuo K; Ross MS; Machida H; Blake EA; Roman LD
J Gynecol Oncol; 2018 Mar; 29(2):e22. PubMed ID: 29400015
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of the history of breast cancer and of hormone therapy in uterine carcinosarcoma.
Uehara T; Onda T; Togami S; Amano T; Tanikawa M; Sawada M; Ikeda S; Kato T; Kasamatsu T
Int J Gynecol Cancer; 2012 Feb; 22(2):280-5. PubMed ID: 22228427
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
10. Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma.
Elshaikh MA; Modh A; Jhingran A; Biagioli MC; Coleman RL; Gaffney DK; Harkenrider MM; Heskett K; Jolly S; Kidd E; Lee LJ; Li L; Portelance L; Sherertz T; Venkatessan AM; Wahl AO; Yashar CM; Small W
Gynecol Oncol; 2020 Aug; 158(2):460-466. PubMed ID: 32475772
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy improves overall survival when added to surgery and chemotherapy for uterine carcinosarcoma: a surveillance, epidemiology, and end results analysis.
Squires BS; Quinn TJ; Nandalur SR; Jawad MS
Int J Clin Oncol; 2021 Dec; 26(12):2282-2294. PubMed ID: 34427803
[TBL] [Abstract][Full Text] [Related]
12. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
Rojas C; Tian C; Powell MA; Chan JK; Bateman NW; Conrads TP; Rocconi RP; Jones NL; Shriver CD; Hamilton CA; Maxwell GL; Casablanca Y; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):67-77. PubMed ID: 32029291
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes.
Manzerova J; Sison CP; Gupta D; Holcomb K; Caputo TA; Parashar B; Nori D; Wernicke AG
Gynecol Oncol; 2016 May; 141(2):225-230. PubMed ID: 26896827
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of brachytherapy and external beam radiation therapy for early stage, node-negative uterine carcinosarcoma.
Patel N; Hegarty SE; Cantrell LA; Mishra MV; Showalter TN
Brachytherapy; 2015; 14(5):606-12. PubMed ID: 26166579
[TBL] [Abstract][Full Text] [Related]
15. Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea.
Kim SI; Ha HI; Eoh KJ; Lim J; Won YJ; Lim MC
Front Oncol; 2022; 12():874037. PubMed ID: 35463304
[TBL] [Abstract][Full Text] [Related]
16. Rare uterine cancer: carcinosarcomas. Review from histology to treatment.
Artioli G; Wabersich J; Ludwig K; Gardiman MP; Borgato L; Garbin F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):98-104. PubMed ID: 25468677
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence with improved survival of gynecologic carcinosarcoma: A population-based study.
Salman L; Brudner Y; Silverman BG; Hallak M; Bruchim I
Eur J Obstet Gynecol Reprod Biol; 2021 Nov; 266():106-110. PubMed ID: 34624737
[TBL] [Abstract][Full Text] [Related]
19. Black race independently predicts worse survival in uterine carcinosarcoma.
Erickson BK; Doo DW; Zhang B; Huh WK; Leath CA
Gynecol Oncol; 2014 May; 133(2):238-41. PubMed ID: 24613675
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival.
Odei B; Boothe D; Suneja G; Werner TL; Gaffney DK
Am J Clin Oncol; 2018 Aug; 41(8):784-791. PubMed ID: 28121642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
